America Handing MRNA Lead: Investors Reassess Biotech
A political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
Auto rebalancing and capital gains management covers how automated tweaks can curb tax impact while preserving strategy.
28,655 articlesA political shift in the United States is denting confidence in mRNA medicine, with funding drying up and manufacturi...
Pay transparency is surfacing a bigger problem: firms publish pay ranges but struggle to explain how they set actual ...
As AI compute ramps up, memory has become a bottleneck. Intel’s 2021 $9 billion NAND sale to SK Hynix is drawing rene...
Investors are turning to a Buffett-inspired approach to generate steady income. This article breaks down a five-stock...
A private equity buyer has acquired the publishing stake in two Taylor Swift co-written hits, signaling a new frontie...
XRP is testing a critical price level in 2026 as regulatory clarity improves and ETF access expands. Analysts debate ...
ANSEM surged 299% over the past week, reviving momentum in Solana's memecoin scene and lifting overall ecosystem acti...
A veteran alchemy of service, fundraising and persistence, Lindsey Graham's rise illustrates how personal history int...
A seasoned Wall Street investor reveals a sizable bet on Avalanche, arguing the platform’s treasury mechanics and sca...
As the Fed stays steady on rates, investors debate whether crypto should be bought before or after the next rate cut....
MicroStrategy remains tethered to Bitcoin moves, but bullish bets persist as the company expands its digital-asset st...
A fresh stake from Cross Staff Investments in the Akre Focus ETF could signal a manager’s confidence in Akre’s approa...